Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
Authors:
- Xiaofen WenXWXiaofen Wen
- Donatella CoradduzzaDCDonatella Coradduzza
- Jiaxin ShenJSJiaxin Shen
- Antonio Mario ScanuAntonio Mario Scanu
- Maria Rosaria MuroniMMMaria Rosaria Muroni
- Matteo MassiddaMMMatteo Massidda
- Vincenzo RalloVRVincenzo Rallo
- Ciriaco CarruCiriaco Carru
- Andrea AngiusAndrea Angius
- Maria Rosaria De MiglioMaria Rosaria De Miglio
Open Access
Abstract
Minimal Residual Disease (MRD) detection has emerged as an independent factor in clinical and pathological cancer assessment offering a highly effective method for predicting recurrence in colorectal cancer (CRC). The ongoing research initiatives such as the DYNAMIC and CIRCULATE-Japan studies, have revealed the potential of MRD detection based on circulating tumor DNA (ctDNA) to revolutionize management for CRC patients. MRD detection represents an opportunity for risk stratification, treatment guidance, and early relapse monitoring. Here we overviewed the evolving landscape of MRD technology and its promising applications through the most up-to-date research and reviews, underscoring the transformative potential of this approach. Our primary focus is to provide a point-to-point perspective and address key challenges relating to the adoption of ctDNA-based MRD detection in the clinical setting. By identifying critical areas of interest and hurdles surrounding clinical significance, detection criteria, and potential applications of basic research, this article offers insights into the advancements needed to evaluate the role of ctDNA in CRC MRD detection, contributing to favorable clinical options and improved outcomes in the management of CRC.Keywords
Funding Information
- Fondazione di Sardegna
This publication has 78 references indexed in Scilit:
- The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminatorEuropean Journal of Surgical Oncology, 2015
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancerAnnals of Oncology, 2015
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgeryGut, 2015
- Telehealth Personalized Cancer Risk Communication to Motivate Colonoscopy in Relatives of Patients With Colorectal Cancer: The Family CARE Randomized Controlled TrialJournal of Clinical Oncology, 2014
- Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2009
- Adjuvant Therapy for completely resected Stage II Colon CancerCochrane Database of Systematic Reviews, 2008
- Type 2 dıabetes mellıtus and CA 19-9 levelsWorld Journal of Gastroenterology, 2007
- Adjuvant Therapy for completely resected stage II Colon Cancer2005
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerNew England Journal of Medicine, 2004
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004